Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center
Daxor (DXR) has expanded its blood volume analysis (BVA) services to a major 735-bed Midwest healthcare facility. The healthcare center will implement Daxor's ezBVA Lab service for outpatient cardiovascular care, focusing on patients with heart failure and hypertension.
Blood samples will be processed at Daxor's CLIA-certified Tennessee facility, providing comprehensive BVA results within 24 hours. The BVA diagnostic offers 98% accuracy in fluid management data, helping clinicians optimize patient care. The service is fully reimbursable through CPT codes for both inpatient and outpatient settings under public and private insurance plans.
Daxor (DXR) ha ampliato i suoi servizi di analisi del volume sanguigno (BVA) in una importante struttura sanitaria del Midwest con 735 letti. Il centro sanitario implementerà il servizio ezBVA Lab di Daxor per la cura cardiovascolare ambulatoriale, concentrandosi sui pazienti con insufficienza cardiaca e ipertensione.
I campioni di sangue saranno elaborati presso la struttura certificata CLIA del Tennessee di Daxor, fornendo risultati BVA completi entro 24 ore. La diagnostica BVA offre un'accuratezza del 98% nei dati di gestione dei fluidi, aiutando i clinici a ottimizzare le cure per i pazienti. Il servizio è completamente rimborsabile attraverso i codici CPT sia per le strutture ospedaliere che per quelle ambulatoriali, sotto i piani assicurativi pubblici e privati.
Daxor (DXR) ha ampliado sus servicios de análisis de volumen sanguíneo (BVA) en un importante centro de salud del Medio Oeste con 735 camas. El centro de salud implementará el servicio ezBVA Lab de Daxor para el cuidado cardiovascular ambulatorio, enfocándose en pacientes con insuficiencia cardíaca e hipertensión.
Las muestras de sangre se procesarán en la instalación certificada por CLIA en Tennessee de Daxor, proporcionando resultados BVA completos en 24 horas. El diagnóstico BVA ofrece un 98% de precisión en los datos de manejo de fluidos, ayudando a los clínicos a optimizar la atención al paciente. El servicio es totalmente reembolsable a través de los códigos CPT tanto para entornos hospitalarios como ambulatorios bajo planes de seguros públicos y privados.
Daxor (DXR)는 중서부의 735병상 규모의 주요 의료 시설에 혈액량 분석(BVA) 서비스를 확장했습니다. 이 의료 센터는 심부전 및 고혈압 환자 중심으로 Daxor의 ezBVA Lab 서비스를 도입할 것입니다.
혈액 샘플은 Daxor의 CLIA 인증 테네시 시설에서 처리되며, 24시간 이내에 포괄적인 BVA 결과를 제공합니다. BVA 진단은 체액 관리 데이터에서 98%의 정확도를 제공하여 임상의가 환자 치료를 최적화하는 데 도움을 줍니다. 이 서비스는 공공 및 민간 보험 계획에 따라 입원 및 외래 환경 모두에서 CPT 코드를 통해 전액 환급 가능합니다.
Daxor (DXR) a élargi ses services d'analyse du volume sanguin (BVA) à un important établissement de santé du Midwest comptant 735 lits. Le centre de santé mettra en œuvre le service ezBVA Lab de Daxor pour les soins cardiovasculaires ambulatoires, en se concentrant sur les patients souffrant d'insuffisance cardiaque et d'hypertension.
Les échantillons de sang seront traités dans la structure certifiée CLIA du Tennessee de Daxor, fournissant des résultats BVA complets en 24 heures. Le diagnostic BVA offre une précision de 98 % dans les données de gestion des fluides, aidant les cliniciens à optimiser les soins aux patients. Le service est entièrement remboursable via des codes CPT pour les environnements hospitaliers et ambulatoires sous les plans d'assurance publics et privés.
Daxor (DXR) hat seine Dienstleistungen zur Analyse des Blutvolumens (BVA) auf eine bedeutende Gesundheitseinrichtung im Mittleren Westen mit 735 Betten ausgeweitet. Das Gesundheitszentrum wird den ezBVA Lab-Service von Daxor für die ambulante kardiovaskuläre Versorgung implementieren, wobei der Fokus auf Patienten mit Herzinsuffizienz und Bluthochdruck liegt.
Blutproben werden in der CLIA-zertifizierten Einrichtung in Tennessee von Daxor verarbeitet, die umfassende BVA-Ergebnisse innerhalb von 24 Stunden liefert. Die BVA-Diagnostik bietet eine Genauigkeit von 98% bei den Daten zur Flüssigkeitsmanagement, was den Klinikern hilft, die Patientenversorgung zu optimieren. Der Service ist vollständig über CPT-Codes sowohl für stationäre als auch für ambulante Einrichtungen unter öffentlichen und privaten Versicherungsplänen erstattungsfähig.
- Expansion into major 735-bed healthcare facility
- Service is fully reimbursable through insurance
- No capital expenditure required for healthcare facilities
- 98% diagnostic accuracy rate
- None.
Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care
Oak Ridge, TN, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into a leading Midwest healthcare facility. This 735-bed medical campus will integrate Daxor’s blood volume analysis (BVA) testing into its outpatient care, enhancing precision in fluid management and patient outcomes.
The program specifically targets patients with heart failure, hypertension, and other cardiovascular conditions where precise fluid management is critical to care. Blood samples will be expedited to Daxor's Tennessee-based ezBVA Lab, a CLIA-certified facility featuring state-of-the-art equipment that delivers comprehensive BVA results within 24 hours.
"Precise volume management is at the heart of effective cardiovascular care, and this expansion continues to widen the ezBVA footprint in the Midwest," explained Michael Feldschuh, Daxor’s CEO and President. "Our BVA diagnostic provides clinicians with
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is the accuracy rate of Daxor's BVA diagnostic technology?
How quickly does Daxor's ezBVA Lab deliver blood volume analysis results?
What types of patients will benefit from DXR's BVA testing at the Midwest facility?
Is Daxor's ezBVA Lab service covered by insurance?
